Navigation Links
Surveyed Experts Indicate that Biogen Idec's Adentri Has Advantages Over Nitroglycerin in the Treatment of Acute Heart Failure
Date:3/25/2009

Adentri Will Earn Decision Resources' Clinical Gold Standard Status for Acute Heart Failure in 2012, According to a New Report from Decision Resources

WALTHAM, Mass., March 25 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed cardiologists indicate that a therapy's effect on the rate of mortality is the attribute that most influences their prescribing decisions in acute heart failure. Clinical data and the opinions of interviewed thought leaders indicate that Biogen Idec's Adentri has advantages in this attribute over nitroglycerin, the benchmark therapy in the market.

The new report entitled Acute Heart Failure: Finding Positive Outcomes in an Evidence Poor Indication finds that an agent with superior reduction in the rate of mortality compared with nitroglycerin would earn a 50 percent patient share in the United States and a 55 percent patient share in Europe, according to our survey of U.S. and European cardiologists.

In 2008, Decision Resources' proprietary clinical gold standard for acute heart failure was Scios/Johnson & Johnson's Natrecor. Interviewed experts generally regard Natrecor as being similarly efficacious as the benchmark therapy, nitroglycerin, but with a slightly better safety profile (e.g. fewer associated headaches). Based on available data and expert opinion, Adentri will earn gold-standard status for acute heart failure in 2012, following its approval for the indication. Adentri has competitive advantages because it will be one of the first adenosine A1 receptor antagonists for use in acute heart failure.

"Interviewed physicians believe that this class of drugs and, particularly, Adentri can provide a feasible and safe therapy when used in combination with loop diuretics," said Decision Resources Analyst Amir Mobasheri. "Interviewed physicians indicated that they prefer this oral agent and believe it will have the advantage of enhancing diuresis while preserving renal function."

About the Report

Acute Heart Failure: Finding Positive Outcomes in an Evidence Poor Indication is a DecisionBase 2009 report. DecisionBase 2009 is a decision-support tool that provides in-depth analysis of unmet need, physician expectations of new therapies and commercial dynamics to help pharmaceutical companies optimize their investments in drug development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Decision Resources                              Decision Resources, Inc.
    Christopher Comfort                             Elizabeth Marshall
    781-296-2597                                    781-296-2563
    ccomfort@dresources.com                         emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. World Vision Index of Concern: Half of Americans Surveyed Said They Would Be Willing to Pay More Taxes to Combat AIDS
2. Eighty-Nine Percent of Surveyed Rheumatologists Say They Will Prescribe Roche/Chugais Actemra for Rheumatoid Arthritis
3. Surveyed Neurologists in Both the U.S. and Europe Would Welcome an Antiepileptic Drug That is Administered Once-Daily
4. Half of Full-Time Employees Surveyed Dont Understand Health Insurance Coverage for Cancer-Related Medical Expenses
5. Surveyed Gastroenterologists Indicate That Humira Has Advantages Over Remicade in Maintaining Clinical Remission of Crohns Disease
6. Less Than Two-Thirds of Surveyed Pharmacy Directors Expect to Reimburse Both Onglyza and Alogliptin Once They are Available for the Treatment of Type 2 Diabetes
7. As a Result of the Jupiter Trial, 65 Percent of Surveyed MCO Pharmacy Directors Will Reimburse Crestor for Patients with Elevated hsCRP
8. Surveyed Oncologists Indicate that Avastin has Advantages over Temodar/Temodal in Increasing Overall Survival of High-Grade Glioma
9. Surveyed Experts Indicate That Xarelto Has Advantages Over Lovenox in the Treatment of Venous Thromboembolism in Medically Ill Patients
10. Research Links TV/Video Game Playing With Child Obesity; Health Experts Back a New Approach
11. MultiVu Video Feed: PUBLIC HEALTH EXPERTS CONVENE TO DISCUSS THE TREATMENT AND PREVENTION OF RABIES
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on June 21 ... brings up a new, often overlooked aspect of head lice: the parasite’s ability to live ... not a common occurrence, but a necessary one in the event that lice have simply ...
(Date:6/25/2016)... ... , ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department ... in recognition of their exemplary accomplishments in worksite health promotion. , The Wellness at ... Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one of 42 ...
(Date:6/24/2016)... PASADENA, CA (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. ... he would lash out at his family verbally and physically. , “When something upset him, ... table, he would use it. He would throw rocks at my other children and say ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway ... call for a minimum wage raise to $12 an hour by 2020 and then adjusting ... restore the lost value of the minimum wage, assure the wage floor does not erode ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... actively feeding the Frederick area economy by obtaining investment capital for emerging technology ... past 2½ years that have already resulted in more than a million dollars ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 The Academy of ... recommendations that would allow biopharmaceutical companies to ... entities that make formulary and coverage decisions, a move ... of new medicines. The recommendations address restrictions ... appear on the drug label, a prohibition that hinders ...
(Date:6/24/2016)...   Pulmatrix, Inc ., (NASDAQ: PULM ... announced today that it was added to the Russell ... comprehensive set of U.S. and global equity indexes on ... milestone for Pulmatrix," said Chief Executive Officer Robert ... progress in developing drugs for crucial unmet medical needs, ...
(Date:6/23/2016)... Any dentist who has made an implant supported ... Many of them do not even offer this as a ... laboratory costs involved. And those who ARE able to offer ... high cost that the majority of today,s patients would not ... Zadeh , founder of Dental Evolutions Inc. and inventor of ...
Breaking Medicine Technology: